Ensysce Biosciences Stock Today
| ENSC Stock | USD 0.59 0.07 11.26% |
Performance8 of 100
| Odds Of DistressOver 75
|
Ensysce Biosciences is trading at 0.5857 as of the 21st of November 2024, a 11.26 percent decrease since the beginning of the trading day. The stock's open price was 0.66. Ensysce Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Ensysce Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of February 2018 | Category Healthcare | Classification Health Care |
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614 PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company has 19.57 M outstanding shares of which 6.35 M shares are currently shorted by private and institutional investors with about 0.12 trading days to cover. More on Ensysce Biosciences
Moving against Ensysce Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ensysce Stock Highlights
| CEO President | Lynn Kirkpatrick | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEnsysce Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ensysce Biosciences' financial leverage. It provides some insight into what part of Ensysce Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ensysce Biosciences (ENSC) is traded on NASDAQ Exchange in USA. It is located in 7946 Ivanhoe Avenue, La Jolla, CA, United States, 92037 and employs 7 people. Ensysce Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.83 M. Ensysce Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 19.57 M outstanding shares of which 6.35 M shares are currently shorted by private and institutional investors with about 0.12 trading days to cover.
Ensysce Biosciences currently holds about 3.15 M in cash with (10.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1.
Check Ensysce Biosciences Probability Of Bankruptcy
Ownership AllocationEnsysce Biosciences holds a total of 19.57 Million outstanding shares. Roughly 76.57 percent of Ensysce Biosciences outstanding shares are held by general public with 1.17 (percent) owned by insiders and only 22.26 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Ensysce Ownership Details
Ensysce Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Ubs Group Ag | 2024-06-30 | 0.0 | |
| Sabby Management Llc | 2024-06-30 | 314.4 K | |
| Citadel Advisors Llc | 2024-06-30 | 86.3 K | |
| Geode Capital Management, Llc | 2024-06-30 | 46.1 K | |
| Renaissance Technologies Corp | 2024-09-30 | 22.4 K | |
| Vanguard Group Inc | 2024-09-30 | 18.2 K | |
| Xtx Topco Ltd | 2024-06-30 | 13.2 K | |
| Virtu Financial Llc | 2024-06-30 | 11.3 K | |
| Tower Research Capital Llc | 2024-06-30 | 8.3 K | |
| Blackrock Inc | 2024-06-30 | 975 |
Ensysce Biosciences Historical Income Statement
Ensysce Stock Against Markets
Ensysce Biosciences Corporate Management
| MSE MBA | Chief Officer | Profile | |
| Geoffrey Birkett | Chief Officer | Profile | |
| Jeffrey Millard | Chief Officer | Profile | |
| Linda Pestano | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.94) | Revenue Per Share 0.274 | Quarterly Revenue Growth (0.63) | Return On Assets (1.32) | Return On Equity (4.28) |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.